MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction.

Madhu V Singh,P. Swaminathan,Elizabeth D. Luczak,W. Kutschke,R. Weiss,Mark E. Anderson,Mark E. Anderson

DOI: https://doi.org/10.1016/j.yjmcc.2012.01.021

IF: 5.763

2012-05-01

Journal of Molecular and Cellular Cardiology

Abstract:

What problem does this paper attempt to address?

Myeloid Differentiation Protein-88 Signaling Mediates Heart Failure

Wei-Qian Chen,Chuanfu Li,Hai-Bin Ruan,Xuan Jiang,Xin Qi,Xiang Gao

DOI: https://doi.org/10.1016/j.cardfail.2007.06.395

IF: 6.592

2007-01-01

Journal of Cardiac Failure

Abstract:Introduction: TLR-mediated NFκB activation is regarded as one new potential indicator in heart failure. Myeloid differentiation protein-88 (MyD88) functions as an essential adaptor and deletion of MyD88 regulates atherosclerosis and myocarditis. However, the in vivo role of MyD88 in heart failure has not been clearly dissected. Hypothesis: MyD88 may play a role in regulating heart failure. Methods: (1)Generate transgenic mice with myocardium-specific dominant negative mutant of MyD88 (dnMyD88), which encodes the TIR domain (amino acids 161-296). (2)Analyze histological, molecular characteristics and cardiac function of dnMyD88 mice. (3)Analyze underlying pathological signaling pathways. Results: (1)dnMyD88 mice expressed transgene specifically in the myocardium. (2)dnMyD88 mice showed heart failure with enlargement of cardiomyocytes (WGA staining) and severe interstitial fibrosis (Masson's staining). RT-PCR of myocardium RNA indicated upregulated hypertrophic markers in dnMyD88 mice [atrial natriuretic factor (ANF): by 235.7%, P < 0.01; brain natriuretic peptide (BNP): by 1547%, P < 0.01]. The ratio of heart weight to tibia length (HW/TL), index for cardiac hypertrophy, was increased by 30.31% at 20 weeks old (P < 0.01). Evaluation of left ventricular (LV) cardiac contractility indicated increased end-diastolic dimension (LVEDD: by 72.82%, P < 0.01); decreased posterior wall thickness in diastole (PWTD: by 41.98%, P < 0.05) and decreased fractional shortening (FS%: by 228.8%, P < 0.01). (3)dnMyD88 mice exhibited short life-span (within 32 weeks). (4)dnMyD88 mice was identified with gradual phosphorylation of Akt and GSK3-β at 8, 16 and 20 weeks old. Conclusions: These data provide the first direct evidence that abnormal MyD88 signaling leads to heart failure.View Large Image Figure ViewerDownload Hi-res image Download (PPT)
MyD88-dependent Interplay Between Myeloid and Endothelial Cells in the Initiation and Progression of Obesity-Associated Inflammatory Diseases.

Minjia Yu,Hao Zhou,Junjie Zhao,Nengming Xiao,Sanjoy Roychowdhury,David Schmitt,Bingqing Hu,Richard M. Ransohoff,Clifford V. Harding,Amy G. Hise,Stanley L. Hazen,Anthony L. DeFranco,Paul L. Fox,Richard E. Morton,Paul E. Dicorleto,Maria Febbraio,Laura E. Nagy,Jonathan D. Smith,Jian-an Wang,Xiaoxia Li

DOI: https://doi.org/10.1084/jem.20131314

2014-01-01

The Journal of Experimental Medicine

Abstract:Low-grade systemic inflammation is often associated with metabolic syndrome, which plays a critical role in the development of the obesity-associated inflammatory diseases, including insulin resistance and atherosclerosis. Here, we investigate how Toll-like receptor-MyD88 signaling in myeloid and endothelial cells coordinately participates in the initiation and progression of high fat diet-induced systemic inflammation and metabolic inflammatory diseases. MyD88 deficiency in myeloid cells inhibits macrophage recruitment to adipose tissue and their switch to an M1-like phenotype. This is accompanied by substantially reduced diet-induced systemic inflammation, insulin resistance, and atherosclerosis. MyD88 deficiency in endothelial cells results in a moderate reduction in diet-induced adipose macrophage infiltration and M1 polarization, selective insulin sensitivity in adipose tissue, and amelioration of spontaneous atherosclerosis. Both in vivo and ex vivo studies suggest that MyD88-dependent GM-CSF production from the endothelial cells might play a critical role in the initiation of obesity-associated inflammation and development of atherosclerosis by priming the monocytes in the adipose and arterial tissues to differentiate into M1-like inflammatory macrophages. Collectively, these results implicate a critical MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases.
MyD88 protein destabilization mitigates NF-κB-dependent protection against macrophage apoptosis

Duško Lainšček,Simon Horvat,Klemen Dolinar,Filip Ivanovski,Rok Romih,Sergej Pirkmajer,Roman Jerala,Mateja Manček-Keber

DOI: https://doi.org/10.1186/s12964-024-01930-1

IF: 7.525

2024-11-23

Cell Communication and Signaling

Abstract:Various signaling pathways are essential for both the innate immune response and the maintenance of cell homeostasis, requiring coordinated interactions among them. In this study, a mutation in the caspase-1 recognition site within MyD88 abolished inflammasome-dependent negative regulation, causing phenotypic changes in mice with some similarities to human NEMO-deficiencies. The MyD88 D162E mutation reduced MyD88 protein levels and colon inflammation in DSS-induced colitis mice but did not affect cytokine expression in bone marrow-derived macrophages (BMDMs). However, compared to MyD88 wt counterparts, MyD88 D162E BMDMs had increased oxidative stress and dysfunctional mitochondria, along with reduced prosurvival Bcl-xL and BTK expression, rendering cells more prone to apoptosis, exacerbated by ibrutinib treatment. NF-κB activation by lipopolysaccharide mitigated this sensitive phenotype. These findings underscore the importance of MyD88 wt signaling for NF-κB activation, protecting against macrophage premature apoptosis at resting state. Targeting MyD88 quantity rather than just its signaling could be a promising strategy for MyD88-driven lymphoma treatment.

cell biology
MyD88 in myeloid cells promotes angiotensin II-induced vascular inflammation and is associated with all-cause mortality and incident heart failure in humans with arterial hypertension

S Finger,S Wild,A Schulz,J Wild,M Molitor,C Mueller,T Zeller,A Daiber,T Muenzel,M Radsak,I Fleming,M Andrade-Navarro,P Wild,P Wenzel

DOI: https://doi.org/10.1093/eurheartj/ehad655.2321

IF: 39.3

2023-11-01

European Heart Journal

Abstract:Abstract Background Angiotensin II (AngII) causes hypertension and promotes vascular accumulation of inflammatory cells. We aimed to determine how myeloid factor of differentiation 88 (MyD88) contributes to vascular dysfunction and arterial hypertension in mice and humans. Methods Male C57BL/6 as well as MyD88-/-, LysMCre/wtMyD88LSL/LSL, LysMCre/wt, TLR2-/-, TLR4-/-, TLR7-/- and TLR9-/- were investigated in the AngII-model of hypertension (1 mg/kg/d for 7days). Biodata analyses were performed in the Gutenberg-Health Study (GHS), a population based cohort. In addition, we performed computational analyses of known hypertension-related genes from genome-wide association studies (GWAS) to investigate whether they preferentially interact with MyD88 in the human protein network. Results MyD88 deficiency attenuated AngII-induced blood pressure increase and endothelial dysfunction in conductance and resistance vessels. Vascular mRNA expression levels of vcam-1, nos2, nox2 were decreased in AngII-infused MyD88-/- mice compared to C57BL/6 controls. Flow cytometric analyses revealed that AngII-induced aortic accumulation of CD11b+Ly6Chi inflammatory monocytes was significantly dampened in MyD88-/- mice. AngII increased mRNA expression of cd62L, cd68 and ccl2, which was blocked in MyD88-/- mice, indicating a role of MyD88 for myeloid cell activation and differentiation. Additionally, aortic interferon-g+ NK cells and mRNA levels of interleukin-12 and interleukin-1b were reduced in AngII-treated MyD88-/- mice. Bone marrow transfer experiments demonstrated a vasoprotective effect of MyD88 deficiency in bone marrow-derived cells, and selective expression of MyD88 in LysMCre/wtMyD88LSL/LSL mice restored AngII-induced pathology, revealing that myelomonocytic cells drives vascular dysfunction in a MyD88-dependent manner. Furthermore, data from 1,274 individuals in the GHS indicated, that MyD88 mRNA expression was associated with all cause mortality and incident chronic heart failure after a median follow-up of 11.6 years. Computational analysis of the human protein interaction network demonstrated that MyD88 is significantly connected to proteins encoded by genetic loci associated with blood pressure traits in multiple GWAS. Conclusion We provide evidence, that MyD88 expressed by myelomonocytic cells promotes AngII-induced vascular dysfunction and arterial hypertension. MyD88 might be used as an inflammatory diagnostic marker for the risk of death in hypertensive patients.

cardiac & cardiovascular systems
A mathematical model using stress-induced genetic variation mechanisms to prevent emergence of resistant bacteria

A. Sotto,J. Lavigne

Abstract:The manuscript concerning commentary on the study by Obolski and Hadany for BMC Medicine is now ready. The title was revised Page 3: a brief explanation of the three strategies for non-experts was provided. Page 3: several references were removed Page 4: a sentence was removed For your information, there is an error in reference 37 of Obolski’s manuscript. We corrected this error in the commentary.
Overexpressing Dominant Negative MyD88 Induces Cardiac Dysfunction in Transgenic Mice

WeiQian Chen,ChuanFu Li,Xuan Jiang,HaiBin Ruan,Xin Qi,Li Liu,QingShun Zhao,Xiang Gao

DOI: https://doi.org/10.1007/s11434-010-4080-9

2010-01-01

Chinese Science Bulletin

Abstract:Myeloid differentiation protein-88 (MyD88) is a crucial adaptor protein in the innate immune response. A protective role for MyD88 in normal cardiac function has been proposed in a surgical hypertrophic model. To assess the in vivo role of MyD88 in cardiac remodeling, we generated transgenic mice with cardiac-restricted expression of a dominant negative mutant of MyD88 (dnMyD88). Surprisingly, dnMyD88 transgenic mice displayed characteristic features of heart failure; including heart weight increase, cardiomyocytes enlargement, interstitial fibrosis, and re-expression of “fetal” genes. Echocardiographic examination of dnMyD88 hearts revealed dilated chamber volume and reduced cardiac contractility. DnMyD88 mice died from heart failure before they were 7 months old, as shown by Kaplan-Meier analysis. Additionally, the heart failure phenotype of dnMyD88 mice was associated with abnormal activation of the Akt/GSK-3β signaling pathway. These data provide the first evidence that normal MyD88 signaling is crucial for maintaining the physiological function of the adult heart.
Inhibition of MyD88 by a Novel Inhibitor Reverses Two-Thirds of the Infarct Area in Myocardial Ischemia and Reperfusion Injury

Yan Miao,Zuochuan Ding,Zhimiao Zou,Yang,Min Yang,Xiaoqian Zhang,Zeyang Li,Liang Zhou,Limin Zhang,Xue Zhang,Dunfeng Du,Fengchao Jiang,Ping Zhou

2020-01-01

American journal of translational research

Abstract:Cardiomyocytes, macrophages, and fibroblasts play important roles in inflammation and repair during myocardial ischemia/reperfusion injury (MIRI). Myeloid differentiation primary response 88 (MyD88) is upregulated in immunocytes, cardiomyocytes, and fibroblasts during MIRI. MyD88 induces the secretion of proinflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α), while fibroblasts are recruited and activated to mediate cardiac remodeling. The aim of this study was to assess the anti-MIRI effect and mode of action of the novel MyD88 inhibitor TJ-M2010-5. We synthesized TJ-M2010-5 and identified its target by co-immunoprecipitation, after which we established a murine MIRI model and tested the protective effect of TJ-M2010-5 by immunohistochemistry, flow cytometry, real-time PCR, and western blotting. Neonatal rat cardiomyocytes subjected to anoxia/reoxygenation were also isolated and their supernatants used to stimulate cardiac macrophagocytes and fibroblasts in vitro. MyD88 was found upregulated during the early and late phases after MIRI. The MyD88 inhibitor considerably improved cardiac function, reduced cardiomyocyte apoptosis, reduced IL-1β, IL-6, and TNF-α secretion, and inhibited CD80+CD86+MHCII+ macrophage and fibroblast migration. Moreover, TJ-M2010-5 markedly inhibited Toll-like receptor/MyD88 signaling in vivo and in vitro. Thus, our findings highlight TJ-M2010-5 as a potential therapeutic agent for MIRI treatment.
CaMKII is a RIP3 Substrate Mediating Ischemia- and Oxidative Stress–induced Myocardial Necroptosis

Ting Zhang,Yan Zhang,Mingyao Cui,Li Jin,Yimei Wang,Fengxiang Lv,Yuli Liu,Wen Zheng,Haibao Shang,Jun Zhang,Mao Zhang,Hongkun Wu,Jiaojiao Guo,Xiuqin Zhang,Xinli Hu,Chun-Mei Cao,Rui-Ping Xiao

DOI: https://doi.org/10.1038/nm.4017

IF: 82.9

2016-01-01

Nature Medicine

Abstract:Regulated necrosis (necroptosis) and apoptosis are crucially involved in severe cardiac pathological conditions, including myocardial infarction, ischemia-reperfusion injury and heart failure. Whereas apoptotic signaling is well defined, the mechanisms that underlie cardiomyocyte necroptosis remain elusive. Here we show that receptor-interacting protein 3 (RIP3) triggers myocardial necroptosis, in addition to apoptosis and inflammation, through activation of Ca(2+)-calmodulin-dependent protein kinase (CaMKII) rather than through the well-established RIP3 partners RIP1 and MLKL. In mice, RIP3 deficiency or CaMKII inhibition ameliorates myocardial necroptosis and heart failure induced by ischemia-reperfusion or by doxorubicin treatment. RIP3-induced activation of CaMKII, via phosphorylation or oxidation or both, triggers opening of the mitochondrial permeability transition pore and myocardial necroptosis. These findings identify CaMKII as a new RIP3 substrate and delineate a RIP3-CaMKII-mPTP myocardial necroptosis pathway, a promising target for the treatment of ischemia- and oxidative stress-induced myocardial damage and heart failure.
The innate immune regulator MyD88 dampens fibrosis during zebrafish heart regeneration

Pinelopi Goumenaki,Stefan Günther,Khrievono Kikhi,Mario Looso,Rubén Marín-Juez,Didier Y R Stainier

DOI: https://doi.org/10.1038/s44161-024-00538-5

Abstract:The innate immune response is triggered rapidly after injury and its spatiotemporal dynamics are critical for regeneration; however, many questions remain about its exact role. Here we show that MyD88, a key component of the innate immune response, controls not only the inflammatory but also the fibrotic response during zebrafish cardiac regeneration. We find in cryoinjured myd88-/- ventricles a significant reduction in neutrophil and macrophage numbers and the expansion of a collagen-rich endocardial population. Further analyses reveal compromised PI3K/AKT pathway activation in the myd88-/- endocardium and increased myofibroblasts and scarring. Notably, endothelial-specific overexpression of myd88 reverses these neutrophil, fibrotic and scarring phenotypes. Mechanistically, we identify the endocardial-derived chemokine gene cxcl18b as a target of the MyD88 signaling pathway, and using loss-of-function and gain-of-function tools, we show that it controls neutrophil recruitment. Altogether, these findings shed light on the pivotal role of MyD88 in modulating inflammation and fibrosis during tissue regeneration.
Innate Immune Nod1/RIP2 Signaling is Essential for Cardiac Hypertrophy, but Requires Mitochondrial Antiviral Signaling Protein (MAVS) for Signal Transductions and Energy Balance

Han-Bin Lin,Kotaro Naito,Yena Oh,Gedaliah Farber,Georges Kanaan,Alan Valaperti,Fayez Dawood,Liyong Zhang,Guo Hua Li,David Smyth,Mark Moon,Youan Liu,Wenbin Liang,Benjamin Rotstein,Dana J. Philpott,Kyoung-Han Kim,Mary-Ellen Harper,Peter P. Liu,Dana Philpott

DOI: https://doi.org/10.1161/circulationaha.119.041213

IF: 37.8

2020-10-29

Circulation

Abstract:Background: Cardiac hypertrophy is a key biological response to injurious stresses such as pressure overload and when excessive can lead to heart failure. Innate immune activation by danger signals, through intracellular pattern recognition receptors such as nucleotide-binding oligomerization domain-containing protein 1(Nod1) and its adaptor receptor-interacting protein 2 (RIP2), might play a major role in cardiac remodeling and progression to heart failure. We hypothesize that Nod1/RIP2 are major contributors to cardiac hypertrophy, but may not be sufficient to fully express the phenotype alone. Methods: To elucidate the contribution of Nod1/RIP2 signaling to cardiac hypertrophy, we randomized Nod1 -/- , RIP2 -/- or wild-type (WT) mice to transverse aortic constriction (TAC) or sham operations. Cardiac hypertrophy, fibrosis, and cardiac function were examined in these mice. Results: Nod1 and RIP2 proteins were up-regulated in the heart after TAC, and this was paralleled by increased expression of mitochondrial proteins, including mitochondrial antiviral signaling protein (MAVS). Nod1 -/- and RIP2 -/- mice subjected to TAC exhibited better survival, improved cardiac function and decreased cardiac hypertrophy. Downstream signal transduction pathways that regulate inflammation and fibrosis including NF-κB and MAPK-GATA4/p300, were reduced in both Nod1 -/- and RIP2 -/- mice after TAC compared with WT mice. Co-immunoprecipitation of extracted cardiac proteins and confocal immunofluorescence microscopy showed that Nod1/ RIP2 interaction was robust and that this complex also included MAVS as an essential component. Suppression of MAVS expression attenuated the complex formation, NF-κB signalling and myocyte hypertrophy. Interrogation of mitochondrial function compared in the presence or ablation of MAVS revealed that MAVS serves to suppress mitochondrial energy output and mediate fission/fusion related dynamic changes. The latter is possibly linked to mitophagy during cardiomyocytes stress, which may provide an intriguing link between innate immune activation and mitochondrial energy balance under stress or injury conditions. Conclusions: We have identified that innate immune Nod1/RIP2 signaling is a major contributor to cardiac remodeling following stress. This process is critically joined by and regulated through the mitochondrial danger signal adapter MAVS. This novel complex coordinates remodeling, inflammatory response and mitochondrial energy metabolism in stressed cardiomyocytes. Thus Nod1/RIP2/MAVS signaling complex may represent an attractive new therapeutic approach toward heart failure.

cardiac & cardiovascular systems,peripheral vascular disease
Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy

Elizabeth D. Luczak,Yuejin Wu,Jonathan M. Granger,Mei-ling A. Joiner,Nicholas R. Wilson,Ashish Gupta,Priya Umapathi,Kevin R. Murphy,Oscar E. Reyes Gaido,Amin Sabet,Eleonora Corradini,Wen-Wei Tseng,Yibin Wang,Albert J. R. Heck,An-Chi Wei,Robert G. Weiss,Mark E. Anderson

DOI: https://doi.org/10.1038/s41467-020-18165-6

IF: 16.6

2020-09-04

Nature Communications

Abstract:Abstract Despite the clear association between myocardial injury, heart failure and depressed myocardial energetics, little is known about upstream signals responsible for remodeling myocardial metabolism after pathological stress. Here, we report increased mitochondrial calmodulin kinase II (CaMKII) activation and left ventricular dilation in mice one week after myocardial infarction (MI) surgery. By contrast, mice with genetic mitochondrial CaMKII inhibition are protected from left ventricular dilation and dysfunction after MI. Mice with myocardial and mitochondrial CaMKII overexpression (mtCaMKII) have severe dilated cardiomyopathy and decreased ATP that causes elevated cytoplasmic resting (diastolic) Ca 2+ concentration and reduced mechanical performance. We map a metabolic pathway that rescues disease phenotypes in mtCaMKII mice, providing insights into physiological and pathological metabolic consequences of CaMKII signaling in mitochondria. Our findings suggest myocardial dilation, a disease phenotype lacking specific therapies, can be prevented by targeted replacement of mitochondrial creatine kinase or mitochondrial-targeted CaMKII inhibition.

multidisciplinary sciences
Ca2+/calmodulin-dependent protein kinase II inhibition reduces myocardial fatty acid uptake and oxidation after myocardial infarction

Yidi Meng,Peiwu Ding,Hongfei Wang,Xueke Yang,Zhiyu Wang,Daan Nie,Jie Liu,Yun Huang,Guanhua Su,Jun Hu,Yanwen Su,Xinling Du,Nianguo Dong,Haibo Jia,Hongbing Zhang,Jiaming Zhang,Jingdong Li

DOI: https://doi.org/10.1016/j.bbalip.2022.159120

2022-06-01

Abstract:An AMP-activated kinase (AMPK) signaling pathway is activated during myocardial ischemia and promotes cardiac fatty acid (FA) uptake and oxidation. Similarly, the multifunctional Ca2+/calmodulin-dependent protein kinase II (CaMKII) is also triggered by myocardial ischemia, but its function in FA metabolism remains unclear. Here, we explored the role of CaMKII in FA metabolism during myocardial ischemia by investigating the effects of cardiac CaMKII on AMPK-acetyl-CoA carboxylase (ACC), malonyl CoA decarboxylase (MCD), and FA translocase cluster of differentiation 36 (FAT/CD36), as well as cardiac FA uptake and oxidation. Moreover, we tested whether CaMKII and AMPK are binding partners. We demonstrated that diseased hearts from patients with terminal ischemic heart disease displayed increased phosphorylation of CaMKII, AMPK, and ACC and increased expression of MCD and FAT/CD36. AC3-I mice, which have a genetic myocardial inhibition of CaMKII, had reduced gene expression of cardiac AMPK. In post-MI (myocardial infarction) AC3-I hearts, AMPK-ACC phosphorylation, MCD and FAT/CD36 levels, cardiac FA uptake, and FA oxidation were significantly decreased. Notably, we demonstrated that CaMKII interacted with AMPK α1 and α2 subunits in the heart. Additionally, AC3-I mice displayed significantly less cardiac hypertrophy and apoptosis 2 weeks post-MI. Overall, these findings reveal a unique role for CaMKII inhibition in repressing FA metabolism by interacting with AMPK signaling pathways, which may represent a novel mechanism in ischemic heart disease.

cell biology,biochemistry & molecular biology,biophysics
Blockade of MyD88 Attenuates Cardiac Hypertrophy and Decreases Cardiac Myocyte Apoptosis in Pressure Overload-Induced Cardiac Hypertrophy in Vivo.

TZ Ha,F Hua,YH Li,J Ma,X Gao,J Kelley,AQ Zhao,GE Haddad,DL Williams,IW Browder,RL Kao,CF Li

DOI: https://doi.org/10.1152/ajpheart.00720.2005

2005-01-01

AJP Heart and Circulatory Physiology

Abstract:In this study, we evaluated whether blocking myeloid differentiation factor-88 (MyD88) could decrease cardiac myocyte apoptosis following pressure overload. Adenovirus expressing dominant negative MyD88 (Ad5-dnMyD88) or Ad5-green fluorescent protein (GFP) (Ad5-GFP) was transfected into rat hearts (n = 8/group) immediately followed by aortic banding for 3 wk. One group of rats (n = 8) was subjected to aortic banding for 3 wk without transfection. Sham surgical operation (n = 8) served as control. The ratios of heart weight to body weight (HW/BW) and heart weight to tibia length (HW/TL) were calculated. Cardiomyocyte size was examined by FITC-labeled wheat germ agglutinin staining of membranes. Cardiac myocyte apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay, and myocardial interstitial fibrosis was examined by Masson's Trichrome staining. Aortic banding significantly increased the HW/BW by 41.0% (0.44 +/- 0.013 vs. 0.31 +/- 0.008), HW/TL by 47.2% (42.7 +/- 1.30 vs. 29.0 +/- 0.69), cardiac myocyte size by 49.6%, and cardiac myocyte apoptosis by 11.5%, and myocardial fibrosis and decreased cardiac function compared with sham controls. Transfection of Ad5-dnMyD88 significantly reduced the HW/BW by 18.2% (0.36 +/- 0.006 vs. 0.44 +/- 0.013) and HW/TL by 22.3% (33.2 +/- 0.95 vs. 42.7 +/- 1.30) and decreased cardiomyocyte size by 56.8%, cardiac myocyte apoptosis by 76.2%, as well as fibrosis, and improved cardiac function compared with aortic-banded group. Our results suggest that MyD88 is an important component in the Toll-like receptor-4-mediated nuclear factor-kappaB activation pathway that contributes to the development of cardiac hypertrophy. Blockade of MyD88 significantly reduced cardiac hypertrophy, cardiac myocyte apoptosis, and improved cardiac function in vivo.
Oxidation of calmodulin alters activation and regulation of CaMKII

A J Robison,Danny G Winder,Roger J Colbran,Ryan K Bartlett

DOI: https://doi.org/10.1016/j.bbrc.2007.02.087

2007-04-27

Abstract:Increases in reactive oxygen species and mis-regulation of calcium homeostasis are associated with various physiological conditions and disease states including aging, ischemia, exposure to drugs of abuse, and neurodegenerative diseases. In aged animals, this is accompanied by a reduction in oxidative repair mechanisms resulting in increased methionine oxidation of the calcium signaling protein calmodulin in the brain. Here, we show that oxidation of calmodulin results in an inability to: (1) activate CaMKII; (2) support Thr(286) autophosphorylation of CaMKII; (3) prevent Thr(305/6) autophosphorylation of CaMKII; (4) support binding of CaMKII to the NR2B subunit of the NMDA receptor; and (5) compete with alpha-actinin for binding to CaMKII. Moreover, oxidized calmodulin does not efficiently bind calcium/calmodulin-dependent protein kinase II (CaMKII) in rat brain lysates or in vitro. These observations contrast from past experiments performed with oxidized calmodulin and the plasma membrane calcium ATPase, where oxidized calmodulin binds to, and partially activates the PMCA. When taken together, these data suggest that oxidative stress may perturb neuronal and cardiac function via a decreased ability of oxidized calmodulin to bind, activate, and regulate the interactions of CaMKII.
MICAL1 constrains cardiac stress responses and protects against disease by oxidizing CaMKII

Klitos Konstantinidis,Vassilios J. Bezzerides,Lo Lai,Holly M. Isbell,An-Chi Wei,Yuejin Wu,Meera C. Viswanathan,Ian D. Blum,Jonathan M. Granger,Danielle Heims-Waldron,Donghui Zhang,Elizabeth D. Luczak,Kevin R. Murphy,Fujian Lu,Daniel H. Gratz,Bruno Manta,Qiang Wang,Qinchuan Wang,Alex L. Kolodkin,Vadim N. Gladyshev,Thomas J. Hund,William T. Pu,Mark N. Wu,Anthony Cammarato,Mario A. Bianchet,Madeline A. Shea,Rodney L. Levine,Mark E. Anderson

DOI: https://doi.org/10.1172/jci133181

IF: 19.456

2020-08-04

Journal of Clinical Investigation

Abstract:Oxidant stress can contribute to health and disease. Here we show that invertebrates and vertebrates share a common stereospecific redox pathway that protects against pathological responses to stress, at the cost of reduced physiological performance, by constraining Ca2+/calmodulin-dependent protein kinase II (CaMKII) activity. MICAL1, a methionine monooxygenase thought to exclusively target actin, and MSRB, a methionine reductase, control the stereospecific redox status of M308, a highly conserved residue in the calmodulin-binding (CaM-binding) domain of CaMKII. Oxidized or mutant M308 (M308V) decreased CaM binding and CaMKII activity, while absence of MICAL1 in mice caused cardiac arrhythmias and premature death due to CaMKII hyperactivation. Mimicking the effects of M308 oxidation decreased fight-or-flight responses in mice, strikingly impaired heart function in Drosophila melanogaster, and caused disease protection in human induced pluripotent stem cell–derived cardiomyocytes with catecholaminergic polymorphic ventricular tachycardia, a CaMKII-sensitive genetic arrhythmia syndrome. Our studies identify a stereospecific redox pathway that regulates cardiac physiological and pathological responses to stress across species.

medicine, research & experimental
Activation of CaMKIIδC is a Common Intermediate of Diverse Death Stimuli-induced Heart Muscle Cell Apoptosis

Weizhong Zhu,Anthony Yiu-Ho Woo,Dongmei Yang,Heping Cheng,Michael T. Crow,Rui-Ping Xiao

DOI: https://doi.org/10.1074/jbc.m611507200

2007-01-01

Abstract:Ca2+-calmodulin-dependent protein kinase II (CaMKII) is expressed in many mammalian cells, with the δ isoform predominantly expressed in cardiomyocytes. Previous studies have shown that inhibition of CaMKII protects cardiomyocytes against β1-adrenergic receptor-mediated apoptosis. However, it is unclear whether activation of CaMKII is sufficient to cause cardiomyocyte apoptosis and whether CaMKII signaling is important in heart muscle cell apoptosis mediated by other stimuli. Here, we specifically enhanced or suppressed CaMKII activity using adenoviral gene transfer of constitutively active (CA-CaMKIIδC) or dominant negative (DN-CaMKIIδC) mutants of CaMKIIδC in cultured adult rat cardiomyocytes. Expression of CA-CaMKIIδC promoted cardiomyocyte apoptosis that was associated with increased mitochondrial cytochrome c release and attenuated by co-expression of Bcl-XL. Importantly, isoform-specific suppression of CaMKIIδC with the DN-CaMKIIδC mutant similar to nonselective CaMKII inhibition by the pharmacological inhibitors (KN-93 or AIP) not only prevented CA-CaMKIIδC-mediated apoptosis but also protected cells from multiple death-inducing stimuli. Thus, activation of CaMKIIδC constitutes a common intermediate by which various death-inducing stimuli trigger cardiomyocyte apoptosis via the primary mitochondrial death pathway.
JOSD2 mediates isoprenaline-induced heart failure by deubiquitinating CaMKIIδ in cardiomyocytes

Jiachen Xu,Shiqi Liang,Qinyan Wang,Qingsong Zheng,Mengyang Wang,Jinfu Qian,Tianxiang Yu,Shuaijie Lou,Wu Luo,Hao Zhou,Guang Liang

DOI: https://doi.org/10.1007/s00018-023-05037-7

IF: 8

2024-01-11

Cellular and Molecular Life Sciences

Abstract:Prolonged stimulation of β-adrenergic receptor (β-AR) can lead to sympathetic overactivity that causes pathologic cardiac hypertrophy and fibrosis, ultimately resulting in heart failure. Recent studies suggest that abnormal protein ubiquitylation may contribute to the pathogenesis of cardiac hypertrophy and remodeling. In this study, we demonstrated that deficiency of a deubiquitinase, Josephin domain-containing protein 2 (JOSD2), ameliorated isoprenaline (ISO)- and myocardial infarction (MI)-induced cardiac hypertrophy, fibrosis, and dysfunction both in vitro and in vivo Conversely, JOSD2 overexpression aggravated ISO-induced cardiac pathology. Through comprehensive mass spectrometry analysis, we identified that JOSD2 interacts with Calcium–calmodulin-dependent protein kinase II (CaMKIIδ). JOSD2 directly hydrolyzes the K63-linked polyubiquitin chains on CaMKIIδ, thereby increasing the phosphorylation of CaMKIIδ and resulting in calcium mishandling, hypertrophy, and fibrosis in cardiomyocytes. In vivo experiments showed that the cardiac remodeling induced by JOSD2 overexpression could be reversed by the CaMKIIδ inhibitor KN-93. In conclusion, our study highlights the role of JOSD2 in mediating ISO-induced cardiac remodeling through the regulation of CaMKIIδ ubiquitination, and suggests its potential as a therapeutic target for combating the disease. Please check and confirm that the authors and their respective affiliations have been correctly identified and amend if necessary. All have been checked

cell biology,biochemistry & molecular biology
Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure

Harald J. Maier,Tobias G. Schips,Astrid Wietelmann,Marcus Krüger,Cornelia Brunner,Martina Sauter,Karin Klingel,Thomas Böttger,Thomas Braun,Thomas Wirth

DOI: https://doi.org/10.1073/pnas.1116584109

IF: 11.1

2012-07-02

Proceedings of the National Academy of Sciences

Abstract:Inflammation is a major factor in heart disease. IκB kinase (IKK) and its downstream target NF-κB are regulators of inflammation and are activated in cardiac disorders, but their precise contributions and targets are unclear. We analyzed IKK/NF-κB function in the heart by a gain-of-function approach, generating an inducible transgenic mouse model with cardiomyocyte-specific expression of constitutively active IKK2. In adult animals, IKK2 activation led to inflammatory dilated cardiomyopathy and heart failure. Transgenic hearts showed infiltration with CD11b + cells, fibrosis, fetal reprogramming, and atrophy of myocytes with strong constitutively active IKK2 expression. Upon transgene inactivation, the disease was reversible even at an advanced stage. IKK-induced cardiomyopathy was dependent on NF-κB activation, as in vivo expression of IκBα superrepressor, an inhibitor of NF-κB, prevented the development of disease. Gene expression and proteomic analyses revealed enhanced expression of inflammatory cytokines, and an IFN type I signature with activation of the IFN-stimulated gene 15 (ISG15) pathway. In that respect, IKK-induced cardiomyopathy resembled Coxsackievirus-induced myocarditis, during which the NF-κB and ISG15 pathways were also activated. Vice versa, in cardiomyocytes lacking the regulatory subunit of IKK (IKKγ/NEMO), the induction of ISG15 was attenuated. We conclude that IKK/NF-κB activation in cardiomyocytes is sufficient to cause cardiomyopathy and heart failure by inducing an excessive inflammatory response and myocyte atrophy.

multidisciplinary sciences
MyD88 inhibition attenuates cerebral ischemia-reperfusion injury by regulating the inflammatory response and reducing blood-brain barrier damage

Fangchao Jiang,Chen Xu,Xuehui Fan,Shuai Yang,Wei Fan,Meng li,Jihe Song,Wan Wei,Hongping Chen,Di Zhong,Guozhong Li

DOI: https://doi.org/10.1016/j.neuroscience.2024.05.010

2024-05-16

Neurosciences

Abstract:Highlights • Inhibition of MyD88 attenuates cerebral ischemia-reperfusion injury in mice. • MyD88 activates microglia via IRF5 following cerebral ischemia-reperfusion(CIR) • MyD88 participates in blood-brain barrier damage following CIR. Myeloid differentiation primary response gene 88 (MyD88), a downstream molecule directly linked to Toll-like receptor (TLRs) and IL1 receptor, has been implicated in ischemia-reperfusion injury across various organs. However, its role in cerebral ischemia-reperfusion injury (CIRI) remains unclear. Five transient middle cerebral artery occlusion (tMCAO) microarray datasets were obtained from the Gene Expression Omnibus (GEO) database. We screened these datasets for differentially expressed genes (DEGs) using the GSE35338 and GSE58720 datasets and performed weighted gene co-expression network analysis (WGCNA) using the GSE30655, GSE28731, and GSE32529 datasets to identify the core module related to tMCAO. A protein-protein interaction (PPI) network was constructed using the intersecting DEGs and genes in the core module. Finally, we identified Myd88 was the core gene. In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) validated that TNFα, IL17, and MyD88 signaling pathways were significantly enriched in tMCAO. Subsequently, we investigated the mechanistic role of MyD88 in the tMCAO model using male C57BL/6 mice. MyD88 expression increased significantly 24h after reperfusion. After intraperitoneal administration of TJ-M2010-5, a MyD88-specific inhibitor, during reperfusion, the infarction volumes in the mice were ameliorated. TJ-M2010-5 inhibits the activation of microglia and astrocytes. Moreover, it attenuates the upregulation of inflammatory cytokines TNFα, IL17, and MMP9 while preserving the expression level of ZO1 after tMCAO, thereby safeguarding against BBB disruption. Finally, our findings suggest that MyD88 regulates the IRAK4/IRF5 signaling pathway associated with microglial activation. MyD88 participates in CIRI by regulating the inflammatory response and BBB damage following tMCAO.

clinical neurology
CaMKII-9 Induces Cardiomyocyte Death to Promote Cardiomyopathy and Heart Failure

Mao Zhang,Junxia Zhang,Wenjia Zhang,Qingmei Hu,Li Jin,Peng Xie,Wen Zheng,Haibao Shang,Yan Zhang

DOI: https://doi.org/10.3389/fcvm.2021.820416

IF: 3.6

2022-01-01

Frontiers in Cardiovascular Medicine

Abstract:Heart failure is a syndrome in which the heart cannot pump enough blood to meet the body's needs, resulting from impaired ventricular filling or ejection of blood. Heart failure is still a global public health problem and remains a substantial unmet medical need. Therefore, it is crucial to identify new therapeutic targets for heart failure. Ca2+/calmodulin-dependent kinase II (CaMKII) is a serine/threonine protein kinase that modulates various cardiac diseases. CaMKII-delta 9 is the most abundant CaMKII-delta splice variant in the human heart and acts as a central mediator of DNA damage and cell death in cardiomyocytes. Here, we proved that CaMKII-delta 9 mediated cardiomyocyte death promotes cardiomyopathy and heart failure. However, CaMKII-delta 9 did not directly regulate cardiac hypertrophy. Furthermore, we also showed that CaMKII-delta 9 induced cell death in adult cardiomyocytes through impairing the UBE2T/DNA repair signaling. Finally, we demonstrated no gender difference in the expression of CaMKII-delta 9 in the hearts, together with its related cardiac pathology. These findings deepen our understanding of the role of CaMKII-delta 9 in cardiac pathology and provide new insights into the mechanisms and therapy of heart failure.

MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction.

Myeloid Differentiation Protein-88 Signaling Mediates Heart Failure

MyD88-dependent Interplay Between Myeloid and Endothelial Cells in the Initiation and Progression of Obesity-Associated Inflammatory Diseases.

MyD88 protein destabilization mitigates NF-κB-dependent protection against macrophage apoptosis

MyD88 in myeloid cells promotes angiotensin II-induced vascular inflammation and is associated with all-cause mortality and incident heart failure in humans with arterial hypertension

A mathematical model using stress-induced genetic variation mechanisms to prevent emergence of resistant bacteria

Overexpressing Dominant Negative MyD88 Induces Cardiac Dysfunction in Transgenic Mice

Inhibition of MyD88 by a Novel Inhibitor Reverses Two-Thirds of the Infarct Area in Myocardial Ischemia and Reperfusion Injury

CaMKII is a RIP3 Substrate Mediating Ischemia- and Oxidative Stress–induced Myocardial Necroptosis

The innate immune regulator MyD88 dampens fibrosis during zebrafish heart regeneration

Innate Immune Nod1/RIP2 Signaling is Essential for Cardiac Hypertrophy, but Requires Mitochondrial Antiviral Signaling Protein (MAVS) for Signal Transductions and Energy Balance

Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy

Ca2+/calmodulin-dependent protein kinase II inhibition reduces myocardial fatty acid uptake and oxidation after myocardial infarction

Blockade of MyD88 Attenuates Cardiac Hypertrophy and Decreases Cardiac Myocyte Apoptosis in Pressure Overload-Induced Cardiac Hypertrophy in Vivo.

Oxidation of calmodulin alters activation and regulation of CaMKII

MICAL1 constrains cardiac stress responses and protects against disease by oxidizing CaMKII

Activation of CaMKIIδC is a Common Intermediate of Diverse Death Stimuli-induced Heart Muscle Cell Apoptosis

JOSD2 mediates isoprenaline-induced heart failure by deubiquitinating CaMKIIδ in cardiomyocytes

Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure

MyD88 inhibition attenuates cerebral ischemia-reperfusion injury by regulating the inflammatory response and reducing blood-brain barrier damage

CaMKII-9 Induces Cardiomyocyte Death to Promote Cardiomyopathy and Heart Failure